Deutsche Bank AG Invests $27.60 Million in Lantheus Holdings, Inc. $LNTH

Deutsche Bank AG acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 248,743 shares of the medical equipment provider’s stock, valued at approximately $27,596,000. Deutsche Bank AG owned 0.38% of Lantheus at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Western Wealth Management LLC bought a new stake in shares of Lantheus during the first quarter valued at approximately $25,000. Smartleaf Asset Management LLC increased its stake in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares in the last quarter. Parallel Advisors LLC lifted its position in Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 298 shares during the period. Osterweis Capital Management Inc. bought a new stake in Lantheus during the second quarter worth about $36,000. Finally, Bessemer Group Inc. boosted its stake in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 13th. B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a research report on Monday. Leerink Partners set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $108.11.

Lantheus Price Performance

NASDAQ:LNTH opened at $99.97 on Friday. The firm has a market capitalization of $6.53 billion, a price-to-earnings ratio of 24.15 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The business has a 50 day simple moving average of $104.08 and a 200-day simple moving average of $90.35. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the company earned $1.57 earnings per share. Lantheus’s revenue was up 2.7% on a year-over-year basis. Equities analysts forecast that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.